The aim of the project was to investigate homocysteinemia and Methylentetrahydrofolate reductase (MTHFR) gene (C677T) mutation with vascular diseases. The investigation comprised a total number of 378 subjects divided into two main groups: 194 healthy individuals and 184 patients: 91 with arterial occlusive disease (AOD) and 93 with thrombosis of deep vein (TDV). Concentration of total homocysteine (tHcy) in plasma was determined using the modified immunoenzyme method. Mutation of MTHFR C677T was examined with polymerase chain reaction with CVD StripAssay (ViennaLab Labordiagnostika GmbH) as a segment of 12 mutations of the cardiovascular system. Concentration of tHcy in patients with AOD was 16.3 ± 8.4 μmol/L in men, 14.1 ± 3.3 μmol/L in women and it was statistically significantly increased as compared to healthy subjects from the same gender (p<0.001). Concentration of tHcy in men with TDV was 14.0 ± 3.5 μmol/L, 13.4 ± 3.0 μmol/L in women and it was significantly increased in comparison to healthy subjects (p<0.001). Concentration of homocysteine in plasma of healthy subjects with different genotype of MTHFR C677T showed significantly higher values for TT when compared to CC genotype as well as to CT genotype. Comparison between healthy and sick individuals both separately, AOD and TDV, or as one entity, showed significantly higher values for the genotypes CC and CT, but not for the TT genotype. There was no correlation of MTHFR C677T gene mutations with AOD and TDV.
Project Objectives: The original aims of the project were: 1) to modify, elaborate and introduce an immunoenzyme method for determination of total homocysteine concentration by Frantzen et al., examining the quality parameters of a certain method; 2) to determine reference values of total homocysteine (tHcy) in the Macedonian population; 3) to determine tHcy concentration in patients with arterial occlusive disease (AOD) and thrombosis of deep veins (TDV); 4) to determine the prevalence of C677T mutation of the enzyme methylentetrahydrofolate reductase (MTHFR) in healthy population, in patients with AOB and TDV and 5) to examine the correlation between C677T genotype and serum homocysteine values in the healthy population and in both groups of patients.
Project Results: Modification of immuno-enzyme method by Frantzen et al. consists of shortening the incubation period of immune reactions for 10 minutes and using smaller quantity of rabbit anti-mice antibodies in comparison with the original method. The BIAS of immuno-enzyme method is <7.2%, precision in series CV <6.1% , precision day by day CV <8.2%, recovery from 93 to 114%. The comparison of the modified immuno-enzyme method with the immunoenzyme method with fluorescence polarization has shown high correlation (r=0.9862).
Reference tHcy values in men are 11.57 ± 1.97 μmol/L, whereas in women they are 8.63 ± 2.64 μmol/ L, which means they depend on age.
Concentration of tHcy in patients with AOD was 16.3 ± 8.4 μmol/L in men, 14.1 ± 3.3 μmol/L in women and it was statistically significantly increased as compared to healthy subjects from the same gender (p<0.001). Concentration of tHcy in men with TDV was 14.0 ± 3.5 μmol/L, 13.4 ± 3.0 μmol/L in women and it was significantly increased in comparison to healthy subjects (p<0.001).
In the Macedonian healthy population, C allele was dominant with frequency of 0.645 in MTHFR C677T gene mutation, whereas T allele was found with frequency of 0.355. Frequencies of T and C alleles of the gene of MTHFR C677T were similar in patients with AOD and in patients with TDV. They were also similar in the analysis of the patients as a group with cardiovascular diseases (CAD). The greatest frequency in the Macedonian healthy population of MTHFR C677T gene mutations had the heterozygote gene CT with about 45%, followed by the homozygote for the wild genotype CC with about 42% and the lowest frequency had the genotype TT with 13%. The greatest frequency of MTHFR C677T gene mutations had the heterozygote genotype CT with about 52% in patients with AOD, TDV and CAD as a whole group. Homozygote for the wild genotype CC in all examined groups of patients (AOD, TDV and CAD) was present in 31-36%. The genotype TT had the lowest frequency (13-16%) in patients with AOD, TDV and CAD as a whole. There was no significant difference of MTHFR C677T gene mutations as risk factors for AOD TDV and CAD analyzed as a whole entity. The values of odds ratio in all examined groups ranged from 0.73 to 1.6, indicating that subjects with genotype CT or TT had approximately equal risk for onset of AOD or TDV.
Concentration of homocysteine in plasma of healthy subjects with different genotype of MTHFR C677T showed significantly higher values for TT when compared to CC genotype as well as to CT genotype. Comparison between healthy and sick individuals both separately, AOD and TDV, or as one entity, showed significantly higher values for the genotypes CC and CT, but not for the TT genotype.
There was no correlation of MTHFR C677T gene mutations with AOD and TDV.
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